AAAAAA
Results:
1-14
|
Results: 14
Authors:
Diasio, RB
Citation: Rb. Diasio, Current status of oral chemotherapy for colorectal cancer, ONCOLOGY-NY, 15(3), 2001, pp. 16-20
Authors:
Heslin, MJ
Yan, J
Johnson, MR
Weiss, H
Diasio, RB
Urist, MM
Citation: Mj. Heslin et al., Role of matrix metalloproteinases in colorectal carcinogenesis, ANN SURG, 233(6), 2001, pp. 786-792
Authors:
Salonga, D
Danenberg, KD
Johnson, M
Metzger, R
Groshen, S
Tsao-Wei, DD
Lenz, HJ
Leichman, CG
Leichman, L
Diasio, RB
Danenberg, PV
Citation: D. Salonga et al., Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase, CLIN CANC R, 6(4), 2000, pp. 1322-1327
Authors:
Diasio, RB
Citation: Rb. Diasio, Oral DPD-inhibitory fluoropyrimidine drugs, ONCOLOGY-NY, 14(10), 2000, pp. 19-23
Authors:
Baker, SD
Diasio, RB
O'Reilly, S
Lucas, VS
Khor, SP
Sartorius, SE
Donehower, RC
Grochow, LB
Spector, T
Hohneker, JA
Rowinsky, EK
Citation: Sd. Baker et al., Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil, J CL ONCOL, 18(4), 2000, pp. 915-926
Authors:
Shestopal, SA
Johnson, MR
Diasio, RB
Citation: Sa. Shestopal et al., Molecular cloning and characterization of the human dihydropyrimidine dehydrogenase promoter, BBA-GENE ST, 1494(1-2), 2000, pp. 162-169
Authors:
Diasio, RB
Johnson, MR
Citation: Rb. Diasio et Mr. Johnson, The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil, PHARMACOL, 61(3), 2000, pp. 199-203
Authors:
Chen, L
Smith, L
Johnson, MR
Wang, KS
Diasio, RB
Smith, JB
Citation: L. Chen et al., Activation of protein kinase C induces nuclear translocation of RFX1 and down-regulates c-myc via an intron 1 X box in undifferentiated leukemia HL-60 cells, J BIOL CHEM, 275(41), 2000, pp. 32227-32233
Authors:
Johnson, MR
Wang, KS
Smith, JB
Heslin, MJ
Diasio, RB
Citation: Mr. Johnson et al., Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction, ANALYT BIOC, 278(2), 2000, pp. 175-184
Authors:
Johnson, MR
Hageboutros, A
Wang, KS
High, L
Smith, JB
Diasio, RB
Citation: Mr. Johnson et al., Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil, CLIN CANC R, 5(8), 1999, pp. 2006-2011
Authors:
Diasio, RB
Johnson, MR
Citation: Rb. Diasio et Mr. Johnson, Dihydropyrimidine dehydrogenase: Its role in 5-fluorouracil clinical toxicity and tumor resistance, CLIN CANC R, 5(10), 1999, pp. 2672-2673
Authors:
Diasio, RB
Citation: Rb. Diasio, Clinical implications of dihydropyrimidine dehydrogenase inhibition, ONCOLOGY-NY, 13(7), 1999, pp. 17-21
Authors:
Diasio, RB
Citation: Rb. Diasio, Improving fluorouracil chemotherapy with novel orally administered fluoropyrimidines, DRUGS, 58, 1999, pp. 119-126
Authors:
McLeod, HL
Collie-Duguid, ESR
Vreken, P
Johnson, MR
Wei, X
Sapone, A
Diasio, RB
Fernandez-Salguero, P
van Kuilenberg, ABP
van Gennip, AH
Gonzalez, FJ
Citation: Hl. Mcleod et al., Nomenclature for human DPYD alleles, PHARMACOGEN, 8(6), 1998, pp. 455-459
Risultati:
1-14
|